Neurocrine Begins Phase 2 Trial of Crinecerfont in Children Under 4 Years With Classic CAH Genetic Condition

MT Newswires Live07-02

Neurocrine Biosciences (NBIX) said late Wednesday it has started a phase 2 clinical trial of crinecerfont in children aged 3 months to under 4 years with classic congenital adrenal hyperplasia, a rare genetic condition that results in an enzyme deficiency altering adrenal steroid hormone production.

Crinecerfont is approved in the US as an adjunctive treatment to glucocorticoid replacement to control androgens in adults and pediatric patients 4 years of age and older with classic CAH, according to a statement.

The study will evaluate the safety and tolerability of crinecerfont in about 20 children, with results expected to support a supplemental US new drug application to expand the drug's approved indication to patients younger than 4 years.

Separately, Neurocrine said it has completed enrollment in a phase 2 study in the European Union evaluating the drug in children from birth to under 2 years of age with classic congenital adrenal hyperplasia.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment